

Osteoporosis after adjuvant treatment for early-stage breast cancer

Christensen, Carina Ørts; Jensen, Maj-Britt; Hermann, Anne Pernille; Ewertz, Marianne

Published in:
Danish Medical Journal

Publication date:
2020

Document version:
Final published version

Document license:
CC BY-NC

Citation for pulished version (APA):
Christensen, C. Ø., Jensen, M.-B., Hermann, A. P., & Ewertz, M. (2020). Osteoporosis after adjuvant treatment for early-stage breast cancer. *Danish Medical Journal*, 67(11), Article A04200223.
<https://ugeskriftet.dk/dmj/osteoporosis-after-adjuvant-treatment-early-stage-breast-cancer>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Original Article

Dan Med J 2020;67(11):A04200223

Osteoporosis after adjuvant treatment for early-stage breast cancer

Carina Ørts Christensen^{1, 2}, Maj-Britt Jensen³, Anne Pernille Hermann^{2, 4} & Marianne Ewertz^{1, 2}

1) Department of Oncology, Odense University Hospital, 2) Institute of Clinical Research, University of Southern Denmark, 3) Danish Breast Cancer Cooperative Group, Rigshospitalet, 4) Department of Endocrinology, Odense University Hospital, Denmark

Dan Med J 2020;67(11):A04200223

ABSTRACT

Introduction: Adjuvant treatment of early-stage breast cancer has been associated with bone loss in randomised trials, but evidence from unselected populations is needed. In a single-center study, we assessed the annual percentage change in bone mineral density (&BMD_t) and risk of osteoporosis from two to five years after adjuvant chemotherapy in patients with oestrogen-receptor-positive and oestrogen-receptor-negative tumours.

Methods: Dual energy X-ray absorptiometry (DXA) was performed in 241 recurrence-free Danish breast cancer patients, among whom 157 had a prior DXA scan within two years of chemotherapy ("early"). Linear regression was used to assess &BMD_t in spine and hip according to age, different health-related variables and time since early DXA.

Results: Based on 157 patients, we observed annual decreases in spine BMD of 1.73% (95% confidence interval (CI): -2.01–1.44, $p < 0.001$) and hip BMD of 1.30% (95% CI: -1.51–1.09, $p < 0.001$). Patients aged less than 50 years at diagnosis had a significant decrease in mean spine BMD of 2.23% (95% CI: -2.78–1.68), whereas the decline was more limited in patients aged 50–59 years and patients aged 60 years or older with a mean spine BMD of 1.70% (95% CI: -2.07–1.34) and 0.81% (95% CI: -1.42–0.20), respectively. The results persisted in multivariable analyses. Osteoporosis was diagnosed in 9% of patients, all postmenopausal.

Conclusions: Adjuvant anthracycline-taxane-based chemotherapy followed by endocrine therapy caused bone loss, especially in younger compared with older patients with early-stage breast cancer, confirming the results from randomised trials.

Funding: This work was supported by the Region of Southern Denmark (grant number 13/7078); the University of Southern Denmark (grant number 00-101-000); the Danish Cancer Society (grant number R90-A6210-14-52); the Department of Oncology and Department of Endocrinology, Odense University Hospital; and the Consultant Council Scholarship, Odense University Hospital.

Trial registration: The study was approved by the Ethics Committee in Region of Southern Denmark (Project ID S-20140142) and the Danish Data Protection Board (ID 2008-58-0035).

Adjuvant therapy after surgery for early-stage breast cancer has contributed to an increasing survival, the five-year relative survival rates being close to 90% in the Nordic countries [1]. Today, the recommended duration of adjuvant tamoxifen for premenopausal women is ten years according to the American Society of Clinical Oncology and European Society for Medical Oncology guidelines [2, 3]. In postmenopausal women, aromatase inhibitors (AIs) can be used upfront or as extended adjuvant therapy after 2-5 years of tamoxifen [3]. The combination of a long survival and long treatment duration creates a need to be aware of long-term adverse

effects, e.g. increased risk of osteoporosis and fractures. Few human studies have addressed the effect of adjuvant chemotherapy before initiation of endocrine treatment on bone mass. Most have reported a loss in bone mass, but we [4] and others [5] have not detected such an effect.

The effect of adjuvant endocrine treatment on bone mineral density (BMD) has been studied by dual energy X-ray absorptiometry (DXA) in large randomised trials comparing tamoxifen with AIs for reducing the risk of breast cancer recurrence. These studies included 138 to 424 patients [6, 7]. Both studies demonstrated that use of tamoxifen was associated with an increase in BMD and AIs with a loss in BMD. Several adjuvant trials have reported that an increased risk of fractures is associated with AIs [8, 9]. Loss of BMD is closely related to the risk of fractures. In a cross-sectional study, 200 Chinese breast cancer survivors treated with chemotherapy followed by five years of endocrine therapy were matched with 200 healthy women, and a four-fold increased risk of vertebral fracture was detected [10].

The randomised trials had stringent inclusion and exclusion criteria, so it may be difficult to generalise the results to unselected populations seen in routine clinical practice. Our aim was to evaluate the long-term effect of adjuvant chemotherapy and endocrine therapy on BMD by DXA in a Danish cohort.

METHODS

Patients

Eligible were women aged 18 years or older who had surgery for a histologically verified early-stage breast cancer diagnosed between 2009 and 2012 and received adjuvant systemic treatment according to the national guidelines of the Danish Breast Cancer Cooperative Group at the Department of Oncology, Odense University Hospital, Denmark. In addition, patients had to be free of recurrence since diagnosis.

Patients were excluded if they had been diagnosed with other malignancies or conditions that required chemotherapy within five years prior to their breast cancer, pre-existing osteoporosis, or treatment with bisphosphonates or methotrexate. Patients who had completed five years of follow-up without recurrence of cancer and had no active contact with the department were not included. All patients provided written informed consent to have a DXA and to use results of prior DXAs.

Adjuvant treatments

All patients received adjuvant chemotherapy with epirubicin (90 mg/m²) and cyclophosphamide (600 mg/m²) followed by docetaxel (100 mg/m²). Premenopausal patients with oestrogen receptor (ER) positive tumours received tamoxifen (20 mg daily), whereas postmenopausal patients received an aromatase inhibitor (2.5 mg daily). The hospital provided endocrine treatment free of charge.

Data sources

Baseline data on patients and disease characteristics were abstracted from patient records and pathology reports. Data were derived directly from the DXA scanner at the Osteoporosis Clinic, Department of Endocrinology, Odense University Hospital, and included dates of DXAs, height, weight, T- and Z-scores, area (g), bone mineral content (cm²) and BMD (g/cm²) in the spine, hip, and forearm. Information on health-related questions was collected by use of a questionnaire. Data collection was initiated on 1 November 2014.

Bone densitometry

A total of 157 patients had a DXA within two years since receiving their first cycle of chemotherapy. BMD was measured at the first to the fourth vertebrae of the lumbar spine (L1-L4) and the left hip (total hip) using one of four Hologic Discovery QDR scanners. These DXAs were included in the analyses and referred to as the early

measure of BMD. At the follow-up DXA, each patient was scanned with the same Hologic Discovery QDR scanner that was used for the early DXA, and BMD was measured at the vertebrae of the lumbar spine (L1-L4), the left hip (total hip) and the mid third of the left forearm. The scanners were not cross calibrated; but for each individual scanner, quality standards were tested daily with the Hologic spine phantom. The coefficient of variation of the BMD measurements was 1.0% for the lumbar spine and forearm and 0.9% for the hip. Osteoporosis was defined by the World Health Organization (WHO) as a T-score for BMD ≤ 2.5 standard deviations (SDs) below the mean value expected for a young healthy female adult in the spine and/or the hip. The Z-score describes the number of SDs by which the BMD in an individual differs from the mean value expected for age and sex [11]. All scans were performed by specially trained personnel.

Statistical analyses

Patients with an early DXA were compared with patients without an early DXA by Fisher's exact test. Based on the T-score in spine and/or hip, all patients were categorised as normal BMD, osteopenic or osteoporotic. For patients who had an early DXA and a follow-up DXA, the annual percentage change ($\%BMD_t$) in the spine and hip was calculated as: $((BMD \text{ in follow-up DXA} - BMD \text{ in early DXA})/BMD \text{ in early DXA}) / (\text{time difference in years between follow-up DXA and early DXA}) \times 100$. The mean $\%BMD_t$ in the spine and hip was presented with 95% confidence intervals (95% CI) for all patients and for subgroups. Simple and multivariable linear regression models were used, and model assumptions were checked graphically and with tests. Multivariable analysis included age, calcium/vitamin D supplement, endocrine therapy, smoking, alcohol, exercise, weight change and time from early DXA. The level of statistical significance was set to 5%. Statistical analyses were performed.

Trial registration: The study was approved by the Ethics Committee in Region of Southern Denmark (Project ID S-20140142) and the Danish Data Protection Board (ID 2008-58-0035).

RESULTS

In 2009 through 2012, a total of 496 breast cancer patients received adjuvant chemotherapy for early-stage breast cancer, among whom 125 did not meet the inclusion criteria. Invitations were sent to 371 patients of whom 100 declined participation. Among the 271 patients who accepted a DXA, 30 patients with a mean age of 55 years (range: 43-68 years) were excluded; 25 patients because they had been diagnosed with osteoporosis before breast cancer and five patients due to prior or current treatment with alendronate or methotrexate. In total, 241 patients with a mean age of 52 years (range: 28-77 years) were included in the final analyses. Among these, 157 patients (65%) had an early DXA performed about five months after initiation of chemotherapy (mean 0.40 years, 95% CI: 0.33-0.48). Patients without an early DXA ($n = 84$) were similar in tumour characteristics to patients with an early DXA, but significant differences in menopausal status ($p = 0.04$), endocrine therapy ($p < 0.001$) and smoking ($p = 0.03$) were seen (**Table 1**).

The follow-up DXA revealed that 42% had a normal BMD, 49% had osteopenia and 9% ($n = 22$) had osteoporosis; 21 patients had a T-score ≤ -2.5 , and one patient a vertebral fracture (**Table 2**). The prevalence of osteoporosis was higher in the spine (20 out of 21 patients) than in the hip (one out of 21 patients).

TABLE 1 / Disease and clinical characteristics of 241 Danish patients with early-stage breast cancer who received chemotherapy during 2009-2012. The values are n (%).

	DXA within 2 yrs since chemotherapy			p-value ^a
	no (N _n = 84)	yes (N _y = 157)	patients in total (N _{tot} = 241)	
<i>Age at diagnosis</i>				
< 50 yrs	35 (42)	52 (33)	87 (36)	0.38
50-59 yrs	35 (42)	78 (50)	113 (47)	
≥ 60 yrs	14 (16)	27 (17)	41 (17)	
<i>Menopausal status at diagnosis</i>				
Premenopausal	50 (60)	71 (45)	121 (50)	0.04
Postmenopausal	34 (40)	86 (55)	120 (50)	
<i>Type of surgery</i>				
Lumpectomy	56 (67)	110 (70)	166 (69)	0.66
Mastectomy	28 (33)	47 (30)	75 (31)	
<i>Type of carcinoma</i>				
Ductal	74 (88)	140 (89)	214 (89)	0.78
Lobular	6 (7)	10 (7)	16 (7)	
Others	4 (5)	5 (3)	9 (3)	
DCIS	0	2 (1)	2 (1)	
<i>Tumour size</i>				
0-9 mm	11 (13)	21 (13)	32 (13)	0.23
10-19 mm	30 (36)	73 (47)	103 (43)	
≥ 20 mm	43 (51)	63 (40)	106 (44)	
<i>Histological grade</i>				
Low: I	9 (11)	23 (14)	32 (13)	0.68
Moderate: II	40 (47)	64 (41)	104 (43)	
High: III	31 (37)	64 (41)	95 (40)	
Not graded	4 (5)	6 (4)	10 (4)	
<i>Nodal status</i>				
Negative	37 (44)	73 (46)	110 (46)	0.79
Positive	47 (56)	84 (54)	131 (54)	
<i>Endocrine therapy</i>				
ER negative	33 (39)	30 (19)	63 (26)	< 0.001
Tamoxifen	25 (30)	47 (30)	72 (30)	
Letrozole	9 (11)	57 (36)	66 (27)	
Sequential ^b	17 (20)	23 (15)	40 (17)	
<i>HER2 status</i>				
Negative	59 (70)	118 (75)	177 (73)	0.45
Positive	25 (30)	39 (25)	64 (27)	
<i>Smoking status at diagnosis</i>				
Never/former	61 (73)	133 (85)	194 (80)	0.03
Current	23 (27)	24 (15)	47 (20)	
<i>BMI at follow-up DXA</i>				
Normal: < 25 kg/m ²	29 (35)	64 (41)	93 (39)	0.36
Overweight: 25-30 kg/m ²	27 (32)	54 (34)	81 (33)	
Obese: > 30 kg/m ²	28 (33)	39 (25)	67 (28)	

DCIS = ductal carcinoma in situ; DXA = dual energy X-ray absorptiometry; HER2 = human epidermal growth factor receptor 2; ER = oestrogen receptor.

a) Fisher's exact test.

b) Switch of endocrine therapy between tamoxifen and letrozole, or switch between letrozole and arimidex or exemestane.

TABLE 2 / Prevalence of osteoporosis 2-5 years after adjuvant chemotherapy in 241 Danish early-stage breast cancer patients. The values are n (%).

	Time since chemotherapy				All (mean age: 52 yrs)
	2-3 yrs (mean age: 52 yrs)	3-4 yrs (mean age: 55 yrs)	4-5 yrs (mean age: 52 yrs)	≥ 5 yrs (mean age: 49 yrs)	
Normal BMD	25 (36)	24 (39)	31 (47)	22 (50)	102(42)
Osteopenia	38 (55)	33 (53)	27 (41)	19 (43)	117(49)
Osteoporosis	6 (9)	5 (8)	8 (12)	3 (7)	22 (9)
All patients	69	62	66	44	241

BMD = bone mineral density.

At diagnosis, 63 patients (27%) received a daily supplement of calcium and/or vitamin D. This number increased to 121 (51%) patients during chemotherapy, and further to 176 (74%) among patients after cessation of chemotherapy. The patients received an average of 732 mg of calcium and 25 µg of vitamin D daily.

Changes in bone mineral density measurements

Table 3 shows the annual percentage change in BMD in 157 early-stage breast cancer patients with a decrease in spine BMD of 1.73% (95% CI: -2.01--1.44, p < 0.001), and hip BMD of 1.30% (95% CI: -1.51--1.09, p < 0.001). The median time between early and follow-up DXA was 2.9 years (range: 1.3-5.2 years). In the spine, patients aged less than 50 years at diagnosis had significant decreases with a mean annual percentage change (&BMD_t) of 2.23% (95% CI: -2.78--1.68), whereas patients aged 50-59 years and patients aged 60 years or older had mean &BMD_t decreases of 1.70% (95% CI: -2.07--1.34) and 0.81% (95% CI: -1.42--0.20), respectively. After adjusting the changes for all variables, the relative mean annual decreases at the spine were 0.75% (95% CI: -1.57- 0.08) among patients aged 50-59 years, and 1.59% (95% CI: -2.56--0.62) in patients aged less than 50 years at diagnosis compared with patients aged 60 years or older (p = 0.005). Thus, the absolute losses were significantly lower among the older age groups. Similar observations were made for hip BMD.

TABLE 3 / Annual percentage change and annual percent change in bone mineral density for each category in relation to the reference group in univariable (B₁) and multivariable (B₂) linear regression analyses in lumbar spine and hip in 157 Danish patients with early-stage breast cancer.

	n	Mean Δ BMD, (95% CI), %	Univariable analyses		Multivariable analyses	
			B ₁ (95% CI), %	p-value	B ₂ (95% CI), %	p-value
Lumbar spine						
All patients	51 (18.1)	5 (1.9)	1 (0.4)	57 (20.4)	-	-
Age at diagnosis:						
≥ 60 yrs	157	-1.73 (-2.01--1.44)	-	0.003	0 (ref.)	0.005
50-59 yrs	27	-0.81(-1.42--0.20)	0 (ref.)		0 (ref.)	
< 50 yrs	78	-1.70 (-2.07--1.34)	-0.89 (-1.82-0.03)		-0.75 (-1.57-0.08)	
Calcium/vitamin D:	52	-2.23 (-2.78--1.68)	-1.42 (-2.40--0.44)	0.72	-1.59 (-2.56--0.62)	0.93
No	26	-1.61 (-2.27--0.95)	0 (ref.)		0 (ref.)	
Yes	130	-1.75 (-2.07--1.43)	-0.14 (-0.91-0.63)		0.03 (-0.73-0.80)	
Endocrine therapy:				0.08		0.09
ER-negative ^a	30	-0.96 (-1.56--0.37)	0 (ref.)		0 (ref.)	
Tamoxifen	47	-1.92 (-2.36--1.49)	-0.96 (-2.04-0.12)		-0.05 (-1.00-0.90)	
Letrozole	57	-1.92 (-2.37--1.47)	-0.96 (-2.00-0.08)		-0.92 (-1.77--0.07)	
Sequential ^b	23	-1.83 (-2.95--0.70)	-0.87 (-2.14-0.41)		-0.69 (-1.69-0.32)	
Smoking at diagnosis:				0.43		0.48
Never/former	133	-1.77 (-2.09--1.46)	0 (ref.)		0 (ref.)	
Current	24	-1.45 (-2.15--0.76)	0.32 (-0.47-1.11)		0.28 (-0.50-1.05)	
Alcohol consumption:				0.13		0.31
0 U/wk	20	-1.29 (-2.29--0.30)	0 (ref.)		0 (ref.)	
1-7 U/wk	112	-1.91 (-2.25--1.57)	-0.62 (-1.65-0.41)		-0.36 (-1.22-0.51)	
≥ 8 U/wk	24	-1.23 (-1.77--0.69)	0.06 (-1.22-1.35)		0.21 (-0.85-1.28)	
Exercise after chemotherapy:				0.64		0.78
0-1 day/wk	13	-1.72 (-2.62--0.81)	0 (ref.)		0 (ref.)	
2-4 days/wk	85	-1.85 (-2.26--1.44)	-0.13 (-1.40-1.14)		-0.04 (-1.06-0.99)	
5-7 days/wk	58	-1.56 (-2.02--1.09)	0.16 (-1.15-1.48)		0.17 (-0.88-1.23)	
Weight change ^c :				0.32		0.25
Loss: < 0 kg	67	-1.56 (-1.97--1.15)	0 (ref.)		0 (ref.)	
Gain: ≥ 0 kg	90	-1.85 (-2.24--1.45)	-0.29 (-0.86-0.29)		-0.33 (-0.89-0.23)	
Time from early DXA:				0.04		0.03
> 2.9 yrs	78	-1.43 (-1.76--1.09)	0 (ref.)		0 (ref.)	
≤ 2.9 yrs	79	-2.02 (-2.47--1.56)	-0.59 (-1.15--0.03)		-0.62 (-1.18--0.05)	
Hip						
All patients	157	-1.30 (-1.51--1.09)	-		-	
Age at diagnosis:						
≥ 60 yrs	27	-0.93 (-1.42--0.45)	0 (ref.)	0.25	0 (ref.)	0.055
50-59 yrs	78	-1.33 (-1.59--1.06)	-0.39 (-1.09-0.30)		-0.22 (-0.81-0.37)	
< 50 yrs	52	-1.45 (-1.88--1.02)	-0.52 (-1.26-0.22)		-0.79 (-1.49--0.09)	
Calcium/vitamin D:				0.55		0.93
No	26	-1.17 (-1.62--0.71)	0 (ref.)		0 (ref.)	
Yes	130	-1.34 (-1.57--1.10)	-0.17 (-0.73-0.39)		0.02 (-0.53-0.58)	
Endocrine therapy:				0.01		0.001
ER-negative	30	-0.65 (-1.09--0.22)	0 (ref.)		0 (ref.)	
Tamoxifen	47	-1.19 (-1.52--0.88)	-0.54 (-1.32-0.23)		0.04 (-0.65-0.73)	
Letrozole	57	-1.62 (-1.95--1.30)	-0.97 (-1.71--0.21)		-0.98 (-1.59--0.36)	
Sequential ^b	23	-1.57 (-2.36--0.78)	-0.92 (-1.84-0.01)		-0.81 (-1.53--0.09)	
Smoking at diagnosis:				0.80		0.85
Never/former	133	-1.31 (-1.54--1.09)	0 (ref.)		0 (ref.)	
Current	24	-1.24 (-1.84--0.64)	0.07 (-0.51-0.65)		0.05 (-0.51-0.62)	
Alcohol consumption:				0.08		0.15
0 U/wk	20	-1.23 (-2.01--0.45)	0 (ref.)		0 (ref.)	
1-7 U/wk	112	-1.44 (-1.68--1.19)	-0.21 (-0.96-0.55)		-0.01 (-0.63-0.62)	
≥ 8 U/wk	24	-0.77 (-1.15--0.38)	0.46 (-0.48-1.40)		0.56 (-0.21-1.33)	
Exercise after chemotherapy:				0.64		0.64
0-1 day/wk	13	-1.51 (-2.54--0.49)	0 (ref.)		0 (ref.)	
2-4 days/wk	85	-1.35 (-1.61--1.10)	0.16 (-0.78-1.10)		0.31 (-0.46-1.07)	
5-7 days/wk	58	-1.18 (-1.57--0.80)	0.33 (-0.64-1.29)		0.19 (-0.81-1.19)	
Weight change ^c :				0.19		0.19
Loss: < 0 kg	67	-1.46 (-1.77--1.15)	0 (ref.)		0 (ref.)	
Gain: ≥ 0 kg	90	-1.18 (-1.47--0.90)	0.28 (-0.14-0.70)		0.27 (-0.13-0.68)	
Time from early DXA:				0.02		0.005
> 2.9 yrs	78	-1.06 (-1.30--0.83)	0 (ref.)		0 (ref.)	
≤ 2.9 yrs	79	-1.54 (-1.88--1.20)	-0.48 (-0.89--0.07)		-0.59 (-1.00--0.18)	

Δ BMD_t = annual percentage change in BMD = (BMD at follow-up DXA - BMD at early DXA)/BMD at early DXA/(time difference in yrs between follow-up and early DXA) × 100.

B₁ = change in Δ BMD_t in relation to the reference group; B₂ = change in Δ BMD_t in relation to the reference group, adjusted for all variables listed; BMD = bone mineral density; CI = confidence interval; DXA = dual energy X-ray absorptiometry; ER = oestrogen receptor; ref. = reference.

a) Patients with ER-negative tumours who did not receive endocrine therapy.

b) Endocrine therapy switched between letrozole and tamoxifen, anastrozole or exemestane.

c) Change in weight between "early" DXA and follow-up DXA.

In the spine, patients with ER-negative tumours had a Δ BMD_t decrease of 0.96% (95% CI: -1.56--0.37), whereas patients who received endocrine therapy with tamoxifen, letrozole or sequential treatment, had a Δ BMD_t decrease of 1.92% (95% CI: -2.36--1.49), 1.92% (95% CI: -2.37--1.47), and 1.83% (95% CI: -2.95--0.70), respectively. The differences in annual bone loss between the four treatment groups were not significant (p = 0.09). Furthermore, a longer time interval between DXAs was significantly related to a more limited bone loss (Table 3, p = 0.03). Similar results were observed for hip BMD (Table 3).

DISCUSSION

In this cohort of 157 Danish early-stage breast cancer patients diagnosed between 2009 and 2012 who received adjuvant chemotherapy and endocrine therapy depending on tumour characteristics, we observed annual decreases in spine and hip BMD of 1.73% and 1.30%, respectively. Higher rates of bone loss were observed in younger (< 50 years) than in older (\geq 60 years) women in the hip and especially in the spine. These results agree well with those from a randomised trial reporting decreases in spine, hip and femoral neck BMD of 1.8%, 1.2% and 1.08% [12], respectively, illustrating that our data from an unselected real-world population are in line with the results of a randomised trial.

In another study of postmenopausal early-stage breast cancer patients on AI treatment, those < 55 years had an estimated annual bone loss in the spine of 2.4%, whereas women \geq 75 years had estimated bone loss in the spine of 0.9%. In hip BMD, the < 55 year group had decreases of 1.4% versus 0.9% for the \geq 75 year group [13]. Tamoxifen, a selective oestrogen receptor modulator, has shown different effects depending on the target tissue and on menstrual status. In postmenopausal women, tamoxifen has an oestrogen-agonistic effect on bone with preservation of bone, whereas tamoxifen decreases BMD in premenopausal women [14]. These annual bone losses are consistent with the results of our study.

The higher rate of bone loss observed in younger women than in older women may be explained by the effect of chemotherapy on ovarian function, which may lead to chemotherapy-induced ovarian failure (CIOF) and menopause. A rapid decrease in oestrogen levels is seen at menopause which is accompanied by a shift in bone turnover from a low to a high state. At menopause, bone loss occurs in an initial accelerated phase that lasts for 4-8 years and a subsequent slow phase that lasts indefinitely [15]. During the rapid phase, up to 7% of BMD may be lost per year in premenopausal women with CIOF [16]. In postmenopausal women, a natural annual loss of 1% in spine BMD is observed [17]. A bone loss of 10% corresponds to a reduction of one standard deviation, which may increase the risk of fractures by a factor two to three depending on the scanning site, e.g., lumbar spine or hip [18]. Based on our results, breast cancer patients treated with letrozole or tamoxifen could potentially lose approximately 10% of spine BMD during a five-year treatment period. Since 2015, postmenopausal breast cancer patients have received adjuvant treatments with zoledronic acid twice a year for four years to prevent bone metastases and maintain bone mass [19], whereas premenopausal women have not. Therefore, we recommend monitoring bone status by DXA, especially in breast cancer patients with CIOF, and counselling to reduce risk factors for osteoporosis.

In our study population, 9% (n = 22) of the 241 included patients were diagnosed with osteoporosis at the follow-up DXA. These results are similar to those of a cross-sectional Danish population-based study [20] and to our own results from breast cancer patients receiving adjuvant chemotherapy [4]. Others have reported osteoporosis in 10.7% of breast cancer patients [13]. Thus, our findings are consistent with previous findings.

The main strength of our study is that patients with an early DXA were scanned on the same scanner when they had the follow-up DXA. This made it possible to compare measurements. It is also a strength that the questionnaire was pilot tested before use, which may have contributed to the high response rate of the questionnaire. It is a limitation that the study design included a historical cohort and that not all participants had two measurements of BMD. In patients who had two DXAs, these were not necessarily obtained at the same intervals relative to treatment. This may have resulted in under- or overestimation of bone loss in relation to treatment. We had no blood samples of bone turnover markers, vitamin D status or menopausal status, which is a weakness.

CONCLUSIONS

In this real-world unselected cohort of Danish early-stage breast cancer patients who received adjuvant chemotherapy and endocrine therapy depending on tumour characteristics, we found annual bone losses that followed the pattern of normal physiology of bone metabolism in relation to CIOF and endocrine therapy. The bone losses were consistent with previous results from randomised trials. To act in time, we recommend that breast cancer patients, especially with CIOF, are monitored with DXA and advised to reduce risk factors for osteoporosis.

Ethical approval: All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its subsequent amendments and comparable ethical standards.

Correspondence: Carina Ørts Christensen. E-mail: Carina.Oerts.Christensen@rsyd.dk

Accepted: 4 August 2020

Conflicts of interest: Disclosure forms provided by the authors are available with the full text of this article at Ugeskriftet.dk/dmj

Acknowledgements: A special thanks to all the patients who participated in the study and in particular to the staff at the Department of Oncology and the Osteoporosis Clinic, Department of Endocrinology, Odense University Hospital, Denmark.

LITERATURE

1. NORDCAN. www-dep.iarc.fr/NORDCAN/DK/table23.asp?registry=208&sex=2&time=5&sort=0&submit=%A0%A0Udf%F8r%A0%A0 (16 Jun 2020).
2. Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. *J Clin Oncol* 2014;32:2255-69.
3. Senkus E, Kyriakides S, Ohne S et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015;26(suppl 5):v8-v30.
4. Christensen CO, Cronin-Fenton D, Froslev T et al. Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer. *Support Care Cancer* 2016;24:4229-36.
5. Markopoulos C, Koukouras D, Venizelos V et al. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons. *Breast* 2016;27:27-34.
6. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. *J Clin Oncol* 2008;26:1051-7.
7. Decensi A, Sun Z, Guerrieri-Gonzaga A et al. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. *Breast Cancer Res Treat* 2014;144:321-9.
8. Rabaglio M, Sun Z, Price KN et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Ann Oncol* 2009;20:1489-98.
9. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. *Lancet* 2007;369:559-70.
10. Hsieh E, Wang Q, Zhang R et al. Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps. *BMC Cancer* 2018;18:104.
11. Hernlund E, Svedbom A, Ivergård M et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos* 2013;8:136.
12. Gnant M, Pfeiler G, Dubsky PC et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2015;386:433-43.
13. Kwan ML, Yao S, Laurent CA et al. Changes in bone mineral density in women with breast cancer receiving aromatase

- inhibitor therapy. *Breast Cancer Res Treat* 2018;168:523-30.
14. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). *J Bone Miner Res* 2006;21:1215-23.
 15. Riggs BL, Khosla S, Melton LJ, 3rd. Sex steroids and the construction and conservation of the adult skeleton. *Endocr Rev* 2002;23:279-302.
 16. Shapiro C, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. *J Clin Oncol* 2001;19:3306-11.
 17. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. *Osteoporos Int* 2002;13:105-12.
 18. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996;312:1254-9.
 19. Early Breast Cancer Trialists' Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet* 2015;386:1353-61.
 20. Hansen S, Shanbhogue V, Folkestad L et al. Bone microarchitecture and estimated strength in 499 adult Danish women and men: a cross-sectional, population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure. *Calcif Tissue Int* 2014;94:269-81.